ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 0922 • ACR Convergence 2023

    The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles

    Tomás Cerdó1, Carlos Perez-Sanchez2, Laurel Woodridge3, Mª Angeles Aguirre4, Rafaela Ortega Castro5, Ismael Sánchez-Pareja6, Laura Muñoz-Barrera1, Pedro Segui1, Christian Merlo6, Pedro Ortiz Buitrago7, Desiree Ruiz Vilchez8, Maria del Carmen Abalos-Aguilera8, Pilar Font Ugalde1, Nuria Barbarroja9, Alejandro Escudero10, Elizabeth Jury3 and Chary Lopez-Pedrera11, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 2IMIBIC, Córdoba, Spain, 3Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 4Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 5Hospital Reina Sofía, Cordoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 8Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 9University of Cordoba, Córdoba, Spain, 10SAS, Córdoba, Spain, 11IMIBIC - Reina Sofia Hospital, Córdoba, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) poses a significant challenge at the diagnostic and treatment levels due to its severe multisystem nature and notable heterogeneity in…
  • Abstract Number: 2362 • ACR Convergence 2023

    Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients

    Thierry Sornasse1, Vishal Kakkar2, Rebecca Ross3, Sunhwa Kim4 and Francesco Del Galdo5, 1AbbVie, Inc., North Chicago, IL, 2University of Leeds, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4AbbVie, Inc., South San Francisco, CA, 5University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom

    Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
  • Abstract Number: 0938 • ACR Convergence 2023

    Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum

    Sunhwa Kim1, Thierry Sornasse2, Vishal Kakkar3, Rebecca Ross4, Yingtao Bi5, Hengcheng Hu2, Lisa Hazelwood2, Lauren Reinke-Breen6, jozsef karman7, Chris Butler2, Jennifer Van Camp2 and Francesco Del Galdo8, 1AbbVie, Inc., South San Francisco, CA, 2AbbVie, Inc., North Chicago, IL, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom, 5AbbVie, Inc., Worcester, MA, 6AbbVie, Inc., Vernon Hills, IL, 7AbbVie, Inc., San Francisco, CA, 8University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
  • Abstract Number: 2427 • ACR Convergence 2023

    Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

    Alessandra Ida Celia1, Xiaoping Yang2, Hana Minsky2, Silvia Malvica2, Michelle Petri3, the Accelerating Medicines Partnership in RA/SLE4, Avi Rosenberg5 and Andrea Fava2, 1John Hopkins University of Medicine, Rome, Italy, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4Multiple, Multiple, 5Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: As part of the Accelerating Medicines Partnership (AMP), we discovered that urinary PR3, a neutrophil degranulation product, is associated with histological activity, indicating the…
  • Abstract Number: 0939 • ACR Convergence 2023

    HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease

    David Lauer1, Luca Romano Kolly1, Hubert Gabrys2, Matthias Brunner1, Malgorzata Anna Maciukiewicz1, Thomas Frauenfelder3, Stephanie Tanadini-Lang2, Anne-Christine Uldry4, Manfred Heller4, Kerstin Klein5, Oliver Distler6, Janine Gote-Schniering1 and Britta Maurer7, 1University Hospital Bern, Bern, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University of Bern, Bern, Switzerland, 5Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
  • Abstract Number: 2495 • ACR Convergence 2023

    Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

    Natalie Atallah1, Vahe Panossian2, Xiaoqing Fu1, Claire Cook1 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2American University of Beirut, Beirut, Lebanon, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
  • Abstract Number: 0946 • ACR Convergence 2023

    Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts

    Aurélien Chepy1, Marie Duhamel2, Solange Vivier1, Clément Chauvet1, Lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi1, David Launay1, Michel Salzet2 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3CHU Lille, Institut d’Immunologie, Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France

    Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
  • Abstract Number: 2581 • ACR Convergence 2023

    Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies

    Samir Rachid Zaim1, Adam Savage1, Mark Gillespie1, Christy Bennett1, lynne Becker1, LauraKay Moss2, Marie Feser2, Jess Edison3, Ted R Mikuls4, Michael Holer2, kevin Deane2 and Xiao-Jun Li1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3Walter Reed Military Medical Center, Bethesda, MD, 4Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
  • Abstract Number: 0962 • ACR Convergence 2023

    Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma

    Irene Choi1, Courtney Yu2, Francesco Boin1, Elizabeth Volkmann3, Stephanie Stanford2 and Nunzio Bottini4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of California San Diego, San Diego, CA, 3University of California Los Angeles, Los Angeles, CA, 4University of California, San Francisco, CA

    Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
  • Abstract Number: 2601 • ACR Convergence 2023

    Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning

    kevin cunningham1, Jaeyun Sung2, Benjamin Hur2, VINOD GUPTA2, Matthew Koster2, Cornelia M. Weyand3, David Cuthbertson4, Nader Khalidi5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Rennie Rhee8, Philip Seo12, Peter Merkel8 and Kenneth Warrington2, 1University of Minnesota, Minneapolis, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic School of Medicine and Stanford University, Rochester, MN, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD

    Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
  • Abstract Number: 1608 • ACR Convergence 2023

    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Ayesha Butt1, Rolando Garcia Milian1, George Goshua1, Sean Gu1, Eugenia Chock2, Valentina Restrepo1, John Hwa1, Hyung Chun1, H Michael Belmont3, Kello Nina4, D. Ware Branch5, Michelle Petri6, Jason Knight7, Rohan Willis8, Maria Laura Bertolaccini9, Doruk Erkan10, Alfred lee1, Anish Sharda1 and Alexander Pine11, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Greenwich, CT, 3NYU School of Medicine, New York, NY, 4Northwell Health, Brooklyn, NY, 5University of Utah, Salt Lake City, UT, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7University of Michigan, Ann Arbor, MI, 8University of Texas Medical Branch, Galveston, TX, 9King's College London, London, United Kingdom, 10Hospital for Special Surgery, New York, NY, 11VA Connecticut/Yale School of Medicine, West Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
  • Abstract Number: 1633 • ACR Convergence 2023

    Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease

    Stephanie Finzel1, Andrea Grioni2, Benjamin A Fisher3, Athena S Papas4, Alexandre Avrameas2, Danny Tuckwell2, Jonas Zierer2, Celine Rauld2, Valeria De Luca2, Enrico Ferrero2, Andre Nogueira da Costa2, Rainer Hillenbrand2, Isabelle Isnardi2 and Wolfgang Hueber2, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3University of Birmingham, Birmingham, United Kingdom, 4Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA

    Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
  • Abstract Number: 1637 • ACR Convergence 2023

    IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

    Helena Achten1, Liselotte Deroo2, Kristel De Boeck3, Matthias Jarlborg1, Tine Decruy1, Joke Deprez1, Emilie Dumas1, Dirk Elewaut4 and isabelle peene5, 1Ghent University, Ghent, Belgium, 2Ghent University, Gent, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5University Hospital Ghent, Ghent, Belgium

    Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
  • Abstract Number: 0020 • ACR Convergence 2023

    The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups

    José Miguel Sequí-Sabater1, Carlos Perez-Sanchez2, Clarissa Meoni3, Tomás Cerdó-Ráez4, Maria del Carmen Abalos-Aguilera5, Desiree Ruiz Vilchez5, Francisco Cepas4, Nuria Barbarroja6, Alejandro Escudero7, Mª Angeles Aguirre8, Chary Lopez-Pedrera9 and Lorenzo Beretta10, 1Agencia Valenciana de Salut/ Hospital Universitari de la Ribera/ Unitat de Reumatología, Gandía, Spain, 2IMIBIC, Córdoba, Spain, 3Ospedale Policlinico di Milano, Milan, Italy, 4Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 5Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 6University of Cordoba, Córdoba, Spain, 7SAS, Córdoba, Spain, 8Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 9IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy

    Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology